Literature DB >> 31398326

Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization.

Kathryn M Hastie1, Robert W Cross2, Stephanie S Harkins1, Michelle A Zandonatti1, Anatoliy P Koval3, Megan L Heinrich3, Megan M Rowland3, James E Robinson4, Thomas W Geisbert2, Robert F Garry5, Luis M Branco3, Erica Ollmann Saphire6.   

Abstract

Lassa virus (LASV) causes hemorrhagic fever and is endemic in West Africa. Protective antibody responses primarily target the LASV surface glycoprotein (GPC), and GPC-B competition group antibodies often show potent neutralizing activity in humans. However, which features confer potent and broadly neutralizing antibody responses is unclear. Here, we compared three crystal structures of LASV GPC complexed with GPC-B antibodies of varying neutralization potency. Each GPC-B antibody recognized an overlapping epitope involved in binding of two adjacent GPC monomers and preserved the prefusion trimeric conformation. Differences among GPC-antibody interactions highlighted specific residues that enhance neutralization. Using structure-guided amino acid substitutions, we increased the neutralization potency and breadth of these antibodies to include all major LASV lineages. The ability to define antibody residues that allow potent and broad neutralizing activity, together with findings from analyses of inferred germline precursors, is critical to develop potent therapeutics and for vaccine design and assessment.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lassa virus; antibody; arenavirus; germline; neutralization; protein engineering; structural biology

Mesh:

Substances:

Year:  2019        PMID: 31398326      PMCID: PMC6814208          DOI: 10.1016/j.cell.2019.07.020

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   66.850


  48 in total

1.  Privateer: software for the conformational validation of carbohydrate structures.

Authors:  Jon Agirre; Javier Iglesias-Fernández; Carme Rovira; Gideon J Davies; Keith S Wilson; Kevin D Cowtan
Journal:  Nat Struct Mol Biol       Date:  2015-11       Impact factor: 15.369

2.  Genetic diversity among Lassa virus strains.

Authors:  M D Bowen; P E Rollin; T G Ksiazek; H L Hustad; D G Bausch; A H Demby; M D Bajani; C J Peters; S T Nichol
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.

Authors:  William Dowling; Elizabeth Thompson; Catherine Badger; Jenny L Mellquist; Aura R Garrison; Jeffery M Smith; Jason Paragas; Robert J Hogan; Connie Schmaljohn
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

4.  The signal peptide of the Junín arenavirus envelope glycoprotein is myristoylated and forms an essential subunit of the mature G1-G2 complex.

Authors:  Joanne York; Victor Romanowski; Min Lu; Jack H Nunberg
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

5.  Light-scattering-based analysis of biomolecular interactions.

Authors:  Daniel Some
Journal:  Biophys Rev       Date:  2013-03-06

6.  Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.

Authors:  James E Robinson; Kathryn M Hastie; Robert W Cross; Rachael E Yenni; Deborah H Elliott; Julie A Rouelle; Chandrika B Kannadka; Ashley A Smira; Courtney E Garry; Benjamin T Bradley; Haini Yu; Jeffrey G Shaffer; Matt L Boisen; Jessica N Hartnett; Michelle A Zandonatti; Megan M Rowland; Megan L Heinrich; Luis Martínez-Sobrido; Benson Cheng; Juan C de la Torre; Kristian G Andersen; Augustine Goba; Mambu Momoh; Mohamed Fullah; Michael Gbakie; Lansana Kanneh; Veronica J Koroma; Richard Fonnie; Simbirie C Jalloh; Brima Kargbo; Mohamed A Vandi; Momoh Gbetuwa; Odia Ikponmwosa; Danny A Asogun; Peter O Okokhere; Onikepe A Follarin; John S Schieffelin; Kelly R Pitts; Joan B Geisbert; Peter C Kulakoski; Russell B Wilson; Christian T Happi; Pardis C Sabeti; Sahr M Gevao; S Humarr Khan; Donald S Grant; Thomas W Geisbert; Erica Ollmann Saphire; Luis M Branco; Robert F Garry
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

7.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21

Review 8.  Immune responses and Lassa virus infection.

Authors:  Marion Russier; Delphine Pannetier; Sylvain Baize
Journal:  Viruses       Date:  2012-11-05       Impact factor: 5.048

9.  Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV.

Authors:  Kathryn M Hastie; Sébastien Igonet; Brian M Sullivan; Pierre Legrand; Michelle A Zandonatti; James E Robinson; Robert F Garry; Félix A Rey; Michael B Oldstone; Erica Ollmann Saphire
Journal:  Nat Struct Mol Biol       Date:  2016-04-25       Impact factor: 15.369

10.  Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection.

Authors:  Rami Sommerstein; Lukas Flatz; Melissa M Remy; Pauline Malinge; Giovanni Magistrelli; Nicolas Fischer; Mehmet Sahin; Andreas Bergthaler; Sebastien Igonet; Jan Ter Meulen; Dorothée Rigo; Paolo Meda; Nadia Rabah; Bruno Coutard; Thomas A Bowden; Paul-Henri Lambert; Claire-Anne Siegrist; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2015-11-20       Impact factor: 6.823

View more
  11 in total

1.  Characterizing the Lassa Virus Envelope Glycoprotein Membrane Proximal External Region for Its Role in Fusogenicity.

Authors:  Junyuan Cao; Guangshun Zhang; Minmin Zhou; Yang Liu; Gengfu Xiao; Wei Wang
Journal:  Virol Sin       Date:  2020-09-08       Impact factor: 4.327

Review 2.  Recent Advances in Bunyavirus Glycoprotein Research: Precursor Processing, Receptor Binding and Structure.

Authors:  Ruben J G Hulswit; Guido C Paesen; Thomas A Bowden; Xiaohong Shi
Journal:  Viruses       Date:  2021-02-23       Impact factor: 5.048

3.  ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge.

Authors:  Robert J Fischer; Jyothi N Purushotham; Neeltje van Doremalen; Sarah Sebastian; Kimberly Meade-White; Kathleen Cordova; Michael Letko; M Jeremiah Matson; Friederike Feldmann; Elaine Haddock; Rachel LaCasse; Greg Saturday; Teresa Lambe; Sarah C Gilbert; Vincent J Munster
Journal:  NPJ Vaccines       Date:  2021-03-02       Impact factor: 7.344

4.  Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans.

Authors:  Rodrigo Borrega; Diana K S Nelson; Anatoliy P Koval; Nell G Bond; Megan L Heinrich; Megan M Rowland; Raju Lathigra; Duane J Bush; Irina Aimukanova; Whitney N Phinney; Sophia A Koval; Andrew R Hoffmann; Allison R Smither; Antoinette R Bell-Kareem; Lilia I Melnik; Kaylynn J Genemaras; Karissa Chao; Patricia Snarski; Alexandra B Melton; Jaikin E Harrell; Ashley A Smira; Debra H Elliott; Julie A Rouelle; Gilberto Sabino-Santos; Arnaud C Drouin; Mambu Momoh; John Demby Sandi; Augustine Goba; Robert J Samuels; Lansana Kanneh; Michael Gbakie; Zoe L Branco; Jeffrey G Shaffer; John S Schieffelin; James E Robinson; Dahlene N Fusco; Pardis C Sabeti; Kristian G Andersen; Donald S Grant; Matthew L Boisen; Luis M Branco; Robert F Garry
Journal:  Viruses       Date:  2021-11-21       Impact factor: 5.048

5.  Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies.

Authors:  Adrian S Enriquez; Tierra K Buck; Haoyang Li; Michael J Norris; Alex Moon-Walker; Michelle A Zandonatti; Stephanie S Harkins; James E Robinson; Luis M Branco; Robert F Garry; Erica Ollmann Saphire; Kathryn M Hastie
Journal:  Cell Rep       Date:  2022-05-24       Impact factor: 9.995

Review 6.  Lassa fever - the road ahead.

Authors:  Robert F Garry
Journal:  Nat Rev Microbiol       Date:  2022-09-12       Impact factor: 78.297

7.  Neutralizing Antibodies against Lassa Virus Lineage I.

Authors:  Tierra K Buck; Adrian S Enriquez; Sharon L Schendel; Michelle A Zandonatti; Stephanie S Harkins; Haoyang Li; Alex Moon-Walker; James E Robinson; Luis M Branco; Robert F Garry; Erica Ollmann Saphire; Kathryn M Hastie
Journal:  mBio       Date:  2022-06-22       Impact factor: 7.786

Review 8.  Inter-Lineage Variation of Lassa Virus Glycoprotein Epitopes: A Challenge to Lassa Virus Vaccine Development.

Authors:  Francis Ifedayo Ibukun
Journal:  Viruses       Date:  2020-03-31       Impact factor: 5.048

9.  Antibodies from Sierra Leonean and Nigerian Lassa fever survivors cross-react with recombinant proteins representing Lassa viruses of divergent lineages.

Authors:  Megan L Heinrich; Matthew L Boisen; Diana K S Nelson; Duane J Bush; Robert W Cross; Anatoliy P Koval; Andrew R Hoffmann; Brandon J Beddingfield; Kathryn M Hastie; Megan M Rowland; Irina Aimukanova; Sophia Koval; Raju Lathigra; Viktoriya Borisevich; Mambu Momoh; John Demby Sandi; Augustine Goba; Lkponmwosa Odia; Francis Baimba; John O Aiyepada; Benevolence Ebo; Philomena Eromon; Chinedu Ugwu; Onikepe Folarin; Testimony Olumade; MacDonald N Onyechi; Johnson Etafo; Rashidat Adeyemi; Elijah E Ella; Maryam Aminu; Simji S Gomerep; Matthew Afam Eke; Olusola Ogunsanya; George O Akpede; Danny O Asogun; Sylvanus A Okogbenin; Peter O Okokhere; Johan Holst; Jeffrey G Shaffer; John S Schieffelin; Thomas W Geisbert; Erica Ollmann Saphire; Christian T Happi; Donald S Grant; Robert F Garry; Luis M Branco
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

10.  Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever.

Authors:  Meirong Wang; Ruihua Li; Yaohui Li; Changming Yu; Xiangyang Chi; Shipo Wu; Shulin Liu; Junjie Xu; Wei Chen
Journal:  Viruses       Date:  2021-03-15       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.